Clinical efficacy of BLyS/APRIL Dual-Target therapy in 2 cases of renal manifestations of primary Sjögren’s syndrome

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1288/23d084bcf029497a1f82e976ecfd9748.pdf

Abstract Title *

Clinical efficacy of BLyS/APRIL Dual-Target therapy in 2 cases of renal manifestations of primary Sjögren’s syndrome

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Meng Han 17638731563@163.com The Second Hospital of Jilin University Nephrology Department Changchun China -

Co-author 2

Jingya Yang yangjingya0706@163.com The Second Hospital of Jilin University Nephrology Department Changchun China -

Co-author 3

Feng Xu xufengyd@163.com The Second Hospital of Jilin University Nephrology Department Changchun China *

Co-author 4

Wenpeng Cui wenpengcui@163.com The Second Hospital of Jilin University Nephrology Department Changchun China -

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Objective: To observe the clinical effect of Telitacicept intervention in patients with primary Sjogren's syndrome with renal disease.

Methods

Methods: A retrospective analysis was performed on 2 patients with renal disease of primary Sjogren's syndrome who were admitted to the Rheumatology and Immunology Department of the Second Hospital of Jilin University from January to December 2023 and who met the diagnostic criteria of "Norms for Diagnosis and Treatment of Primary Sjogren's Syndrome" and were treated with Telitacicept intervention.

Results

Result: 1.Case 1 was treated continuous treatment of "hormone + hydroxychloroquine + Telitacicept " regularly for 12 weeks, kidney involvement and inflammatory response indexes decreased, symptoms of dry eyes and dry mouth were relieved, ESSDAI score improved by 44%, ESSPRI score improved by 25%, and the total score of MFI-20 decreased by 3 points;

2. Case 2 was treated with continuous treatment of "mycophenol sodium + Telitacicept " regularly for 4 weeks, and the symptoms of dry mouth and dry eyes were improved, the content of humoral immunoglobulin was reduced, and the inflammatory index was decreased. However, the patient's blood creatinine was repeatedly increased and did not decrease, and medication was stopped after review. ESSDAI score improved by 17%, ESSPRI score improved by 20%, and the total score of MFI-20 decreased by 3 points.

Conclusion

Conclusion: Telitacicept has a certain clinical effect in the treatment of kidney disease in patients with primary Sjogren's syndrome, and its therapeutic effect is related to the duration of administration.

Kewords